Skip to main content
Gary Gordon, MD, Radiology, Kensington, MD

Gary Hart Gordon MD

Nuclear Medicine


Physician

Join to View Full Profile
  • 10810 Connecticut AveKaiser Permanente Kensington Medical CenterKensington, MD 20895

  • Phone+1 301-929-7100

Are you Dr. Gordon?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Gary Gordon, MD is a board certified radiologist in Kensington, Maryland. He is currently licensed to practice medicine in Maryland, Georgia, and District of Columbia.

Education & Training

  • Drexel University College of Medicine/Hahnemann University Hospital
    Drexel University College of Medicine/Hahnemann University HospitalResidency, Radiology-Diagnostic, 1985 - 1986
  • Montefiore Medical Center/Albert Einstein College of Medicine
    Montefiore Medical Center/Albert Einstein College of MedicineResidency, Nuclear Medicine, 1984 - 1985
  • Rutgers Health/Cooperman Barnabas Medical Center
    Rutgers Health/Cooperman Barnabas Medical CenterResidency, Radiology-Diagnostic, 1981 - 1984
  • Georgetown University School of Medicine
    Georgetown University School of MedicineClass of 1981

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 1983 - Present
  • DC State Medical License
    DC State Medical License 1988 - 2027
  • MD State Medical License
    MD State Medical License 1988 - 2026
  • VA State Medical License
    VA State Medical License 1987 - 2026
  • GA State Medical License
    GA State Medical License 2021 - 2024
  • PA State Medical License
    PA State Medical License 1985 - 1988
  • Diagnostic Radiology
    American Board of Radiology Diagnostic Radiology

Press Mentions

  • Ayala Pharmaceuticals Presents Encouraging Preliminary Safety and Efficacy Data in Patients with Recurrent/Metastatic Adenoid Cystic Carcinoma with Progressing Disease and Notch Activating Mutations from Ongoing Phase 2 Clinical Trial at ESMO
    Ayala Pharmaceuticals Presents Encouraging Preliminary Safety and Efficacy Data in Patients with Recurrent/Metastatic Adenoid Cystic Carcinoma with Progressing Disease and Notch Activating Mutations from Ongoing Phase 2 Clinical Trial at ESMOSeptember 30th, 2019